
Opinion|Videos|December 20, 2024
Fixed-Duration Options for CLL
Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite therapy.
Advertisement
Episodes in this series

Now Playing
Content above is prompted by the following:
- A key distinction between preferred upfront therapies for CLL—venetoclax-based regimens and Bruton tyrosine kinase (BTKi)–based regimens—is that venetoclax offers a fixed-duration option, while BTKi therapy is typically continuous. However, studies presented at the 2024 American Society of Hematology annual meeting explored the efficacy and safety of fixed-duration BTKi therapy in the first-line setting. How might adopting fixed-duration BTKi therapy influence treatment choices in the relapsed/refractory CLL setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Zanubrutinib Safe, Effective in Real-World CLL/SLL Cohort
2
Promises and Pitfalls of AI in Health Care
3
Paul Ryan Champions Health Care Policy Reform, AI Amid Government Shutdown
4
Review Outlines Shared Pathways Between CKD, VHD
5















































